| Deutsches Krebsforschungszentrum Patent applications |
| Patent application number | Title | Published |
|---|
| 20120104279 | Fluorescence Light Scanning Microscope Having a Birefringent Chromatic Beam Shaping Device - A fluorescence light scanning microscope ( | 05-03-2012 |
| 20120040334 | Diagnostic Transcript and Splice Patterns of HPV16 in Different Cervical Lesions - The present invention relates to a method for differentiating in a subject with HPV16 between (i) a severe form of HPV16 infection and (ii) a mild form of HPV16 infection based on determining the amount of a first gene product and a second gene product in a sample of a subject and calculating a ratio of the amount of said first gene product and the amount of said second gene product. Further envisaged by the present invention is a composition comprising an oligonucleotide mixture. Also envisaged by the present invention are a kit and a device adapted to carry out the method of the present invention. | 02-16-2012 |
| 20120039912 | RSPONDIN-3 INHIBITION IN BONE DISORDERS - The present invention relates to uses of antagonists of Rspondin-3 (Rspo3) polypeptides or Rspondin-3 nucleic acids. The invention is based on the demonstration that partial deficiency of Rspo3 leads to a significant increase of bone mass. These results indicate a major role for Rspo3 as a bone anabolic marker or target. Thus, the invention also relates to the use of Rspo3 antagonists in the treatment of osteopenia disorders, particularly in conditions associated with increased bone resorption. | 02-16-2012 |
| 20110318363 | Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity - Described are single-stranded new sequences of TT viruses, rearranged TTV sequences and hybrid molecules of a specific TT virus sequence and host cell DNA that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. In addition, it relates to the use of such molecules as gene vectors and artificial chromosomes. | 12-29-2011 |
| 20110300113 | Death Receptor CD95 Controls Neurogenesis of Adult Neural Stem Cells in Vivo and in Vitro - The present invention relates to the activation of the CD95L/CD95 system for inducing neuronal differentiation in vitro and in vivo and the use of CD95L compositions to effect differentiation. | 12-08-2011 |
| 20110275059 | Diagnostic Transcript and Splice Patterns of HR-HPV in Different Cervical Lesions - The present invention relates to a method for differentiating in a subject with HR-HPV between a severe form of HR-HPV infection and a mild form of HR-HPV infection. It further is concerned with a composition comprising a probe oligonucleotide mixture, a device, and a kit for use in conjunction with the method of the invention. | 11-10-2011 |
| 20110249311 | Method and Device for Dynamically Shifting a Light Beam with Regard to an Optic Focussing the Light Beam - For dynamically shifting a light beam ( | 10-13-2011 |
| 20110142811 | MEASLES VIRUS FOR THE ELIMINATION OF UNWANTED CELL POPULATIONS - The present invention concerns recombinant measles virus as a therapeutic, in particular a recombinant measles virus comprising a suicide gene in its genome, a mutated viral hemagglutinin, and a specificity domain specifically recognizing a cancer antigen. Furthermore, it relates to a polynucleotide coding for such a recombinant measles virus and a vector comprising said polynucleotide. The current invention also relates to a method for the manufacture of and a medicament comprising said recombinant measles virus, as well as a method for treating a solid tumor using said recombinant measles virus. | 06-16-2011 |
| 20110123483 | HMGB1 FOR CANCER TREATMENT - The current invention relates to a method for treating a subject suffering from cancer comprising administering to said subject a therapeutically effective dose of High Mobility Group B1 (HMGB1) protein or of a polynucleotide comprising a coding region for an HMGB1 gene in an expressible form. Moreover, it relates to the combination of said method with other cancer treatment regimens. | 05-26-2011 |
| 20110033425 | Parvovirus Having a CPG-Enriched Genome Useful for Cancer Therapy - A parvovirus characterized by a CpG-enriched genome, wherein the genome contains at least 2 additional CpG inserts that are not present in the wild type genome is described as well as the use of said parvovirus, e.g., a parvovirus based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species for the preparation of a pharmaceutical composition, e.g., for the treatment of cancer, preferably pancreas carcinoma, hepatoma or lymphoma. | 02-10-2011 |
| 20110020287 | Parvovirus Cancer Therapy and Combination with Chemotherapy - Described is a pharmaceutical composition containing (a) a parvovirus and (b) a chemotherapeutic agent, preferably as separate entities. The parvovirus might be based on parvovirus H1, LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus (RPV), Rat virus (RV), vectors based on the foregoing viral species, and/or cells capable of actively producing the foregoing viral species. The pharmaceutical composition is beneficial for the treatment of a tumor. Tumors for which a parvovirus or the adjunction of the invention has particular utility include glioma, medulloblastoma, meningioma and pancreatic cancer. Preferred chemotherapeutic agents are gemcitabine and Temozolodine. | 01-27-2011 |
| 20100276585 | METHOD FOR DETERMINING THE CONCENTRATION OF A MOLECULE - The present invention relates to a method for determining the concentration of a first molecule having a chemical structure, which contains a first peptide sequence comprising: (a) obtaining a sample containing the first molecule, (b) providing a reference sample which contains a second molecule having a certain concentration and chemical structure, which contains a second peptide sequence, wherein the chemical structure of the second molecule only differs from the structure of the first molecule in one or more permutations in the first peptide sequence, (c) combining the reference sample and the sample containing the first molecule, (d) identifying at least one fragment peak in a mass spectrum (MS) of the first molecule and the second molecule, wherein the mass difference of the fragment peaks is only caused by the permutation of the at least two different amino acids, and (e) determining the concentration of the first molecule relative to the certain concentration of the second molecule by comparing of the identified peaks. | 11-04-2010 |
| 20100232668 | Method, Computer Program And Workstation For Removing Undesirable Objects From A Digital Medical Image - A method of removing undesirable objects such as bones from a digital medical image is disclosed. In the preferred embodiment, the method comprises the steps of generating a symbolic representation of the medical image, wherein said symbolic representation comprises a directed graph comprising vertices and edges, wherein each pixel or voxel of the digital medical image is associated with an edge of the graph, and wherein the root of said directed graph is not located within said undesirable object; electing, by user input, a site located within said undesirable object; determining a path in the symbolic representation, said path including the edge associated with said elected site and propagating towards the root of said directed graph; visualizing the part of the image associated with said determined path; identifying within said visualized part of the image the transition between the undesired object and the remainder of the image; and removing the part of the image associated with the branch of the graph rooted at said transition between the undesired object and the remainder of the image. | 09-16-2010 |
| 20090242801 | METHOD OF FLUORESCENCE-MICROSCOPICALLY IMAGING A STRUCTURE IN A SAMPLE WITH HIGH THREE-DIMENSIONAL SPATIAL RESOLUTION - For imaging a structure in a sample with three-dimensional spatial resolution, a fluorophore is selected which is transferable by means of an optical transfer signal out of a first into a second photochromic state having specific fluorescence properties, and which displays a return rate back into the first photochromic state. The structure is labeled with the fluorophore. Via a common objective, the sample with the labeled structure is subjected both to the optical transfer signal in a spatially limited transfer-volume, and to an optical excitation signal exciting a portion of the fluorophore being in its second photochromic state for fluorescence in a spatially limited excitation-volume, the transfer-volume and the excitation-volume having a common centre of maximum intensity of the transfer signal and of the excitation signal, and a decrease of intensity of the transfer signal with the distance to the common centre of maximum intensity being substantially stronger than any decrease of the effective return rate of the fluorophore. Fluorescence light emitted by the excited fluorophore is detected. The common centre of maximum intensity is shifted with regard to the sample; and the steps of subjecting and detecting are repeated. | 10-01-2009 |
| 20090082258 | Means and Methods for Treating Advanced Stage Neuroblastoma - The present invention relates to uses of compounds having a structure as shown by formula (I) for the manufacture of a pharmaceutical composition for the treatment of neuroblastoma. Moreover, the present invention encompasses methods of treatment for said diseases. | 03-26-2009 |
| 20080298401 | Device and Method for Creating a Spatial Dose Distribution in a Medium Volume - A device and a method for creating a spatial dose distribution in a medium volume ( | 12-04-2008 |
| 20080234185 | Use of Dmbt1 for Capturing Sulphate and Phosphate Group Exposing Agents - Disclosed is the use of DMBT1, or of the nucleic acid encoding it, for the manufacture of a medicament for the treatment of a patient suffering from a disease caused by an agent, which possesses at least one accessible sulphate and/or at least one accessible phosphate group, uses of DMBT1 as a diagnostic for diagnosing the susceptibility of an individual to sulphate or phosphate groups, as well as methods for diagnosis, prophylaxis or treatment of diseases caused by an agent which possesses at least one accessible sulphate and/or at least one accessible phosphate group. | 09-25-2008 |
